Dr. Kenneth Edelson

Clinical Instructor, MOUNT SINAI SCHOOL OF MEDICINE OF

Member of the Healthcare Council

Council Member Biography

Kenneth Edelson, MD, FAACS, is a Clinical Instructor at Mount Sinai School of Medicine and attending at The Mount Sinai Hospital. He is an NYC Dermatologist in practice for over 25 years and specializes in cosmetic dermatologic surgery and skin cancer. Dr. Edelson uses lasers and IPL's for facial rejuvenation, and treats vascular lesions, pigmentation and cellulite. He has presented cases to many dermatology groups including the New York Academy of Medicine. Dr. Edelson was a Clinical Investigator for the Collagen Corporation and helped to launch the "first" filler, Zyderm in 1982. He is experienced in all fillers including Juvederm, Restylane, Radiesse, Evolence and Botox. Dr. Edelson wrote the chapter on "Fillers and Recontouring The Hand", for the textbook: "Cosmetic Dermatology: A Comprehensive Medical and Surgical Text", to be published soon by Wiley-Blackwell, and a similar lead article as the Master Case Series article of the March 2009 issue of the indexed "Journal of Cosmetic Dermatology". (This is me - Update Profile)

Employment History

2009 - Unspecified: Clinical Instructor, MOUNT SINAI SCHOOL OF MEDICINE OF
1980 - Unspecified: Owner, KENNETH L EDELSON MD

GLG News^SM Analyses by Kenneth Edelson(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.

Cost is key, but not enough!

December 17, 2007

Analysis of:Ipsen and Medicis announce submission of Reloxin(R) in aesthetics to the FDA | www.pipelinereview.com

Lowering cost of Botox is key, but not enough to induce patients to undergo Botox treatments.

Reloxin Gives Allergan's Botox A Run for the Money!

December 13, 2007

Analysis of:Ipsen and Medicis announce submission of Reloxin(R) in aesthetics to the FDA | www.pipelinereview.com

For too long Allergan has monopolized the therapeutic and cosmetic market of botulinum toxin type A, and has taken full advantage of that monopoly by raising the price of Botox almost biannually. Reloxin studies are very favorable when compared to Botox, and may even surpass it in one or two aspects. There is a lesser protein load and therefore less antigenic than Botox and this may lead to a longer lasting effect. Studies already show and support this. In addition, there is a greater diffusion of the toxin from pontiff injection, and this is desirable in certain areas as the large frontalis areas of the face, and certainly in the large areas we tret for hyperhidrosis of the palms, soles and axillae, The conversion rate of units is not to be looked at as a chore of conversion, but as learning a new language. Don't look to convert units to units...just learn the required units of the new toxin. The shelf life appears to be slily longer as well. Cudos to Reloxin-watch out Botox!

New Organiceuticals May Help Bring Back Beauty!

May 29, 2007

Analysis of:http://www.nytimes.com/2007/04/26/fashion/26skin.html?_r=1&ref=health&oref=slogin | www.nytimes.com

All that glitters is not gold...but some might be! Anti-oxidants are the promise of saving our "hides"!

Couldn't agree more

May 28, 2007

Analysis of:FDA May Place Ban on OTC Bleaching Creams | www.carefair.com

Keep Hydroquinones Around!

Non-Invasive Screening of the Skin

May 17, 2007

Analysis of:New tool allows noninvasive screening of skin lesions | www.modernmedicine.com

The company hopes to apply for European regulatory approval next year, with U.S. market approval and launch to follow. The current price of the device is 15,000 EUR. This device promises to be a remarkable time and money saver for medicine. Approximately 80-95% of lesions excised by dermatologists prove non-cancerous when examined histologically. This is wasted time, money and unnecessary anxiety for patients.

View All GLG News ^SM Analyses by Kenneth Edelson